SAN JOSE, Calif., April 30, 2014 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony™ Prenatal Test for detection of common genetic conditions, has announced the election of Kate Falberg to its Board of Directors as well as Chair of the Audit Committee.
Ms. Falberg has had a very successful career in the life sciences industry. She most recently served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC, a biopharmaceutical company. From 1995 to 2001, Ms. Falberg was with Amgen Inc., where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg currently also serves on the board of directors and is the chair of the Audit Committee of both Halozyme Therapeutics, Inc., a biopharmaceutical company, and Medivation, Inc., a biopharmaceutical company.
"We are very pleased to have Kate Falberg join our board. Her extensive experience in both finance and strategy will complement our existing board as we continue to expand our presence in the molecular diagnostics space," said Ken Song, MD, CEO of Ariosa.
About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a global commercial-stage molecular diagnostics company focused on improving overall patient care by developing and delivering innovative, affordable and widely-accessible genetic testing. Our Harmony™ Prenatal Test is a blood test for any pregnant woman that can be used as early as ten weeks into pregnancy. Led by an experienced team, we use our proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony™ Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.